(Alliance News) - AstraZeneca on Friday said its Lynparza treatment produced positive results in its Phase III PROfound trial - which is focused on men with metastatic castration-resistant prostate cancer.
Shares in the blue-chip pharmaceutical firm were 0.4% higher at 8,216.00 pence each in London.
Astra, which is developing the drug with Merck & Co Inc, said the trial showed a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival.
"Overall survival in metastatic castration-resistant prostate cancer has remained extremely challenging to achieve. We are thrilled by these results for Lynparza and we are working with regulatory authorities to bring this medicine to patients as soon as possible," said Jose Baselga, Astra's executive vice president for Oncology research & development.
Lynparza was granted priority review in the US for patients with metastatic castration-resistant prostate cancer who have a homologous recombination repair gene mutation in January 2020, with regulatory reviews ongoing in the EU and other jurisdictions.
Astra and MSD are also exploring additional trials in prostate cancer including the ongoing Phase III PROpel trial, with first data expected in 2021, testing Lynparza as a 1st-line medicine for patients with metastatic castration-resistant prostate cancer in combination with abiraterone acetate versus abiraterone acetate alone.
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)